PROTOKINETIX BLOG

Find out how AAGP® is changing lives through cell survival

As we move forward with clinical research for our anti-aging glycopeptide, AAGP®, we continue to uncover new areas of opportunity for the molecule. See how AAGP® is helping to provide more hope for patients and investors in the areas of ophthalmology, transplants, dermatology and biomanufacturing.

Apr 23, 2019

byncaipen

Ophthalmology

ProtoKinetix AAGP® in Phase 3 Retinal Replacement Program

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) updates it’s stockholders regarding phase 3 of testing using AAGP® in retinal cell replacement therapy at the University of British...Read more

Jan 16, 2019

byncaipen

Ophthalmology

ProtoKinetix Releases Second in a Series of Scientific Update Videos

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX)announces the launch of the second in a series of informational videos by the Principal Investigators in each field currently being...Read more

Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.